Evidence map›Paper›PMID 41322439›Full record

ArticleOpen life sciences2025

Lipoxin A4 improves myocardial ischemia/reperfusion injury through the Notch1-Nrf2 signaling pathway.

Xueyun Yan, Anbang Chen, Yuanqi Gong, Jun Xu, Jinyue Lu, Linjuan Wang, Yunfei Fan, Naijing Gao, Le Zhou, Huaming Cao and 1 more

Abstract read
In one paragraph

Article in Open life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Xueyun YanDepartment of Cardiology, Shi bei Hospital, Shanghai, People's Republic of China.
Anbang ChenDepartment of Pathology, Basic Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Yuanqi GongDepartment of Critical Care Medicine/ICU (Intensive Care Unit), Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Jun XuDepartment of Pathology, Basic Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Jinyue LuDepartment of Cardiology, Shi bei Hospital, Shanghai, People's Republic of China.
Linjuan WangDepartment of Pathology, Basic Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Yunfei FanDepartment of Pathology, Basic Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.
Naijing GaoDepartment of Cardiology, Shi bei Hospital, Shanghai, People's Republic of China.
Le ZhouDepartment of Cardiology, Shi bei Hospital, Shanghai, People's Republic of China.
Huaming CaoDepartment of Cardiology, Shi bei Hospital, Shanghai, People's Republic of China.
Xiaodong KuangDepartment of Pathology, Basic Medical College, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study investigates the mechanism by which lipoxin A4 (LXA4) attenuates myocardial ischemia/reperfusion injury (MIRI). Using a rat MIRI model, we evaluated coronary flow, histopathology, cardiac enzymes (cTnI/CK-MB), oxidative stress markers (superoxide dismutase, SOD; malondialdehyde, MDA; glutathione peroxidase, GSH-Px), and protein expression (neurogenic locus notch homolog protein 1 [Notch1], hairy and enhancer of split 1 [Hes1], nuclear factor-erythroid 2-related factor 2 [Nrf2], β-tubulin). Pharmacological inhibitors

Indexed as

ischemia/reperfusionLXA4microtubulesNotch1-Nrf2.oxidative stress

Identifiers

PMID41322439
PMCPMC12658726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.